Abstract:Objective To investigate the clinical effect of sitagliptin combined with metformin in the treatment of overweight and obese type 2 diabetes mellitus (T2DM). Methods From April 2017 to March 2020 in Nanjing Jiangbei Hospital, 109 cases of overweight and obese patients with T2DM were selected and divided into observation group (n=57) and control group (n=52) randomly. Diet and exercise intervention were given in both groups，and the control group was treated with metformin, while the observation group was treated with sitagliptin and metformin. The clinical effects blood indexes levels and adverse reactions of the two groups were compared before treatment and 16 weeks after treatment, and a foresaid blood indexes including fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), body mass index (BMI), homocysteine (Hcy), total cholesterol (TC), triacylglycerol (TG), high density protein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). Results After 16 weeks of treatment, the total clinical effective rate in the observation group was higher than that in the control group (89.47% vs 67.31%, P<0.01). The levels of FBG, 2hPG, HbA1c, BMI, Hcy, TC, TG and LDL-C in the observation group were lower than those in the control group, while the level of HDL-C was higher than that in the control group (P<0.01). The total adverse reaction rate in the observation group was lower than that in the control group (5.26% vs 19.23%, P<0.05). Conclusion For overweight and obese patients with T2DM, the combination of sitagliptin and metformin can reduce blood sugar and blood lipid levels, and also reduce BMI and Hcy, with less adverse reactions and higher safety.